Section 232 Specialty Pharmaceuticals: Zero-Rate Guidance Effective September 29, 2026

The Section 232 specialty pharmaceuticals framework introduces a significant zero-rate pathway—but only when product category, origin, and entry reporting align. Pharmaceutical importers and customs brokers must translate the September 29, 2026 changes into precise HTSUS mappings, documented eligibility decisions, and reliable ACE entry controls.

Understanding Zero-Rate Eligibility for Specialty Pharmaceuticals

The 0% ad valorem Section 232 rate applies to defined specialty pharmaceuticals and associated ingredients that satisfy one of two pathways. A qualifying product may be a product of an eligible jurisdiction, or it may receive a product-specific determination based on an urgent U.S. health need.

The zero rate is an adjustment to the applicable Section 232 tariff treatment. It does not eliminate the need to classify the merchandise under its ordinary HTSUS provision, report the appropriate Chapter 99 heading, value the goods correctly, or satisfy other admissibility requirements.

Covered Specialty Pharmaceutical Categories

Eligibility is limited to designated categories rather than pharmaceuticals generally. The recognized categories are:

• Pharmaceuticals for which all approved indications are orphan-designated
• Nuclear medicines
• Plasma-derived therapies
• Fertility drugs
• Cell therapy products
• Gene therapy products
• Antibody-drug conjugates
• Medical countermeasures related to chemical, biological, radiological, or nuclear threats
• Animal health products

For this eligibility framework, the categories may include investigational products as well as products approved or authorized by the Food and Drug Administration. Associated ingredients may also qualify when they fall within the applicable definitions. Importers should therefore assess the specific product, ingredient, intended use, development status, and supporting records instead of relying solely on a broad therapeutic label.

Eligible Jurisdictions and Origin Analysis

The eligible jurisdictions are Argentina, Bangladesh, Cambodia, Ecuador, El Salvador, the European Union, Guatemala, India, Indonesia, Japan, Jordan, Malaysia, North Macedonia, the Republic of Korea, Switzerland and Liechtenstein, Taiwan, Thailand, the United Kingdom, and Vietnam.

Eligibility generally depends on the product’s country of origin, not merely its country of export, invoicing location, distribution hub, or manufacturer headquarters. Canada is not included in the eligible-jurisdiction list. Multi-country pharmaceutical supply chains should receive particular scrutiny where active ingredients, intermediates, fill-and-finish operations, packaging, and final processing occur in different jurisdictions.

Preparing ACE and HTSUS Reporting for the September 29 Cutover

The technical corrections take effect for goods entered for consumption, or withdrawn from warehouse for consumption, on or after 12:01 a.m. Eastern Time on September 29, 2026. The controlling event is generally the entry or withdrawal timing, not the vessel arrival date, purchase order date, manufacturing date, or date on the commercial invoice.

This distinction can change the tariff result for shipments arriving near the cutover. Importers and brokers should identify entries likely to cross midnight, verify the relevant time zone, and avoid assuming that pre-arrival documentation establishes the applicable treatment.

Chapter 99 Mapping and Heading 9903.04.70

Broker instructions and tariff databases should be updated to reflect the revised Chapter 99 structure. New HTSUS heading 9903.04.70 provides an additional 0% rate for qualifying pharmaceutical articles used in clinical trials, research and development, or other non-commercial applications.

Use of that heading should be supported by evidence of the product’s actual purpose. Descriptions such as “sample,” “research material,” or “not for resale” may not, by themselves, establish that the shipment qualifies. Compliance files should generally connect the imported article to a clinical protocol, investigational program, research activity, development project, or documented non-commercial use.

The underlying HTSUS classification remains essential. Entry configurations should pair the correct ordinary tariff provision with the applicable Chapter 99 treatment and any required partner-agency data. Automated validations should flag inconsistent combinations before transmission to ACE.

Interaction With the 100% Section 232 Rate

Certain patented pharmaceuticals and associated ingredients became subject to a 100% ad valorem Section 232 rate on July 31, 2026 for Annex III companies. The rate extends on September 29, 2026 to covered products from other companies, subject to applicable exclusions and zero-rate treatment.

Generic pharmaceutical products and associated ingredients are not currently subject to the pharmaceutical Section 232 tariffs. Compliance teams should nevertheless document why a product is treated as generic, specialty, investigational, patented, or otherwise outside the tariff scope. Product-master labels without legal and technical substantiation create avoidable entry risk.

Managing Urgent U.S. Health Need Requests and Audit Support

A specialty pharmaceutical that is not a product of an eligible jurisdiction may still qualify for the 0% Section 232 rate through an urgent U.S. health need determination. Requests are submitted by email to pharma232@bis.doc.gov and should address one product per application.

The request process is product-specific. A determination for one formulation, strength, presentation, ingredient, or manufacturing origin should not automatically be extended to another item without confirming that the determination covers it.

Information Required for a Request

A well-structured submission should include:

• The requesting organization’s identity and contact information
• The HTSUS classification, preferably at the 10-digit level
• The brand name or investigational new drug identifier
• The active ingredient
• The applicable specialty pharmaceutical category
• The country of origin and country of export
• The importer of record’s name and number
• The manufacturer’s name
• A clear explanation of the urgent U.S. health need

The rationale should connect the product to a concrete domestic health need. Relevant considerations may include supply continuity, limited alternatives, patient access, critical treatment requirements, or the consequences of disruption. Unsupported conclusions are generally less persuasive than a concise narrative backed by product, supply, and medical-use documentation.

Entry Controls and Supporting Documentation

Commerce consults with U.S. trade and health authorities when evaluating urgent-need requests, while CBP administers the tariff adjustment at entry summary. CBP may request documentation supporting the claimed treatment.

Importers should maintain a centralized eligibility file containing product specifications, regulatory status, orphan-designation evidence where applicable, country-of-origin analysis, manufacturer information, ingredient records, clinical or non-commercial-use support, and any urgent-need determination. Brokers should receive controlled filing instructions that identify the approved HTSUS and Chapter 99 combinations.

Post-entry monitoring is equally important. Exception reports should identify entries filed without the expected zero-rate heading, products using outdated tariff maps, and claims made without required documentation. These controls help prevent both overpayment and unsupported duty treatment.

Frequently Asked Questions

When Does the Section 232 Specialty Pharmaceutical Zero Rate Take Effect?

The zero-rate implementation and related HTSUS technical corrections apply to goods entered for consumption, or withdrawn from warehouse for consumption, on or after 12:01 a.m. Eastern Time on September 29, 2026. Arrival before that time does not necessarily determine treatment if entry or withdrawal occurs afterward.

Does Origin in an Eligible Jurisdiction Automatically Establish Eligibility?

No. The merchandise must generally qualify both as a covered specialty pharmaceutical or associated ingredient and as a product of an eligible jurisdiction. Importers should document the specialty category and conduct an appropriate origin analysis rather than relying on the shipping country or seller’s address.

Are Investigational Pharmaceuticals Eligible for the 0% Rate?

Investigational products may qualify for purposes of the specialty pharmaceutical framework. Eligibility still depends on the applicable category, origin or urgent-health-need pathway, classification, and supporting documentation. Clinical trial, research and development, and non-commercial shipments may also fall under HTSUS heading 9903.04.70 when its conditions are met.

Are Generic Pharmaceuticals Subject to the Section 232 Pharmaceutical Tariff?

At this time, generic pharmaceutical products and associated ingredients are not subject to the pharmaceutical Section 232 tariffs. Importers should retain evidence supporting generic status, particularly where patent status, animal health applications, formulations, or ingredient relationships could make product treatment unclear.

Does a 0% Section 232 Rate Eliminate All Import Duties?

Generally, no. A 0% Chapter 99 rate means no additional Section 232 duty is imposed under that provision. The ordinary HTSUS duty rate, merchandise processing fee, and any other applicable tariffs, fees, or trade measures may still apply.

Can One Urgent-Need Request Cover Multiple Products?

The process requires one product per application. Companies managing a portfolio should separate requests and maintain product-level records. Closely related products should not be consolidated unless specific filing instructions permit that treatment.

How Stable Software Can Help

Automating Pharmaceutical Entry Compliance

Stable Software helps pharmaceutical importers and customs brokers convert complex tariff requirements into controlled, repeatable workflows. Its trade technology can support product-level HTSUS and Chapter 99 mapping, effective-date management, jurisdiction validation, document retention, broker instructions, and exception reporting across high-volume entry operations.

Automated controls can flag entries that use outdated tariff treatments, lack documented specialty-category eligibility, or conflict with approved origin data. Centralized records also make it easier to support ACE filings, respond to CBP questions, and coordinate urgent-health-need determinations across compliance, regulatory, logistics, and brokerage teams. Learn how Stable Software can strengthen pharmaceutical import compliance before and after the September 29 cutover.

Resources